Pharmaceuticals

NeuroVive Completes Recruitment in the Second Part of its Ongoing KL1333 Clinical Phase Ia/b Study

LUND, Sweden, Dec. 23, 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced the completed recruitment of healthy volunteers in the second part of the company's ongoing Phase Ia/b clinical study with candidate drug KL1333, in development for chroni...

2019-12-23 08:33 1299

Bridge Biotherapeutics Files Investigational New Drug Application for BBT-176, an EGFR TKI for NSCLC

SEONGNAM, South Korea, Dec. 19, 2019 /PRNewswire/ -- Bridge Biotherapeutics Inc., a clinical stage biotech company headquartered in Seongnam, South Korea, announced that the company filed an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) and the Ministry...

2019-12-20 10:19 1252

Merck Licenses Foundational CRISPR Integration Technology to Promega

- Gives scientists a new view into natural cell activity, accelerating drug development DARMSTADT, Germany, Dec. 19, 2019 /PRNewswire/ -- Merck, a leading science and technology company, today announced that it has signed a license agreement providingPromega Corp., a global life science manufact...

2019-12-19 21:00 2363

Asieris Wins Questex's Fierce Innovation Awards - Life Sciences Edition 2019

SHANGHAI, Dec. 19, 2019 /PRNewswire/ -- Asieris, a China-based biotech company specializing in the development and commercialization of new drugs for the treatment of genitourinary tumors and related diseases, announced today that it has been selected as a winner in this year's Fierce Innovation ...

2019-12-19 13:51 2661

Specialised Therapeutics Signs Exclusive Deal for New Haematology Drug

SINGAPORE, Dec. 18, 2019 /PRNewswire/ -- Independent pharmaceutical company Specialised Therapeutics Asia (STA) has signed an exclusive license deal with US-based Onconova Therapeutics (NASDAQ: ONTX), securing commercialisation rights to a new therapy for the treatment of Myelodysplastic Syndrome...

2019-12-18 22:00 2749

Dr. Jie Jack Li joins Shanghai ChemPartner as a Vice President of Discovery Chemistry

SHANGHAI, Dec. 17, 2019 /PRNewswire/ -- Shanghai ChemPartner announced the appointment ofJie Jack Li, Ph.D. as a Vice President of Discovery Chemistry at the Company headquarters inShanghai, China. Dr. Li is an established chemist with over 20 years of experience in both medicinal chemistry and ...

2019-12-18 00:00 1933

MoA Technology implements CDD Vault to manage its crop protection research data

SAN FRANCISCO and OXFORD, England, Dec. 17, 2019 /PRNewswire/ -- MoA Technology Ltd (MoA Tech) and Collaborative Drug Discovery, Inc (CDD) announced today that MoA Tech teams are successfully running CDD Vault, a comprehensive informatics platform for archiving, mining and analysing chemistry and...

2019-12-17 17:00 1284

CMT's Manufacturing Automation Asia Summit draws Automotive, Aerospace, Pharma, Electronics, Chemical Manufacturers to Singapore

SINGAPORE, Dec. 17, 2019 /PRNewswire/ -- Manufacturing Automation Asia organized by Centre for Management Technology (CMT) will be held in advanced manufacturing hub -Singapore, the summit brings together key insights from manufacturers who have already adoptedsmart automation systems

2019-12-17 09:00 4290

Pivotal DREAMM-2 study demonstrated a clinically meaningful overall response rate with belantamab mafodotin (GSK2857916) for patients with relapsed/refractory multiple myeloma

* Overall response rate (ORR) of 31% with 2.5 mg/kg regimen and no new safety signals in heavily pre-treated patient population who were refractory to an immunomodulatory drug and a proteasome inhibitor, and were refractory or intolerant to an anti-CD38 antibody * Data published in The Lancet...

2019-12-17 07:47 7584

etectRx Announces U.S. FDA Clearance of Novel Ingestible Event Marker

ID-Cap System Uses Advanced Wireless Technology to Reliably Track Ingestion Events GAINESVILLE, Florida, Dec. 16, 2019 /PRNewswire/ -- etectRx®, Inc. (etectRx), a privately-held digital health company, has announced U.S. Food and Drug Administration (FDA) clearance of its breakthrough patented i...

2019-12-16 07:06 1525

Drug Manufacturers Eye Analytical Instrumentation to Reduce Operating Costs

SANTA CLARA, California, Dec. 12, 2019 /PRNewswire/ -- The total analytical instrumentation market in pharmaceuticals, biopharmaceuticals, and nutraceuticals generated revenues of $3.05 billion in 2018 and is expected to grow at aCAGR of 7.0% to touch $4.91 billion in 2025. Pharmaceuticals were t...

2019-12-12 23:11 1125

HemoCue AB, the Pioneer and Global leader in Hemoglobin (Hb) Point-of-care Testing (POCT) to Further Strengthen National Activities in the Combat against Anemia in India

HemoCue AB report fruitful discussions, continued support and new activities related to health initiatives, following the participation at the High-Level Business Delegation inNew Delhi and Mumbai, on December 2-4, 2019 STOCKHOLM, Dec. 12, 2019 /PRNewswire/ -- In 2019, Sweden and India celebrate ...

2019-12-12 16:11 855

Human Microbiome Market to Reach $6.08 Billion by 2023, Powered by the High Growth in Over-the-Counter Probiotics

SANTA CLARA, California, Dec. 11, 2019 /PRNewswire/ -- There has been a surge in industry-academia collaborations in thehuman microbiome therapeutics space. The partnerships betweenpharma/biotech companies and academic institutes are bringing together the research expertise of educational organiz...

2019-12-11 23:55 910

iX Biopharma Reports on Outcome of Wafermine End-of-phase 2 Meeting with US FDA

SINGAPORE, Dec. 11, 2019 /PRNewswire/ -- Specialty pharmaceutical company iX Biopharma Ltd(SGX:42C) ("iX Biopharma" or, "the Company") is pleased to announce that it has successfully concluded an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) regarding Wafermine, a sublin...

2019-12-11 22:00 1922

GemVax announced phase II results of GV1001 for Alzheimer's disease treatment at CTAD 2019

SEOUL, South Korea, Dec. 11, 2019 /PRNewswire/ -- The 12th Clinical Trials on Alzheimer's Disease (CTAD) 2019 was held inSan Diego, USA, from December 4-7. At the CTAD, the results of various Alzheimer's disease clinical trials were shared, and it provided a glimpse into the possibility of treati...

2019-12-11 18:40 1280

Xinhua Silk Road: E. China Nanjing Jiangbei New Area aims to develop life and health industry

BEIJING, Dec. 11, 2019 /PRNewswire/ -- Nanjing Jiangbei New Area, a state-level new area in East China'sJiangsu Province, is committed to building a 100 billion-yuan level life and health industrial cluster and becoming a gene city inChina. The news was announced by Luo Qun, a member of the Stan...

2019-12-11 16:52 3209

CStone announces enrollment target reached in the global Phase III VOYAGER trial of avapritinib in Chinese patients with third-line GIST

SUZHOU, China, Dec. 11, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced that the on-going, global Phase III VOYAGER clinical trial of avapritinib, an investigational drug discovered by CStone's partner, Blueprint Medicines, has completed target ...

2019-12-11 11:00 2838

AGC Biologics Expands Plasmid DNA Offering

SEATTLE, Dec. 11, 2019 /PRNewswire/ -- AGC Biologics, a global Contract Development and Manufacturing Organization (CDMO) for Biopharmaceuticals, is significantly expanding its CDMO services with plasmid DNA (pDNA) offerings from itsHeidelberg site in Germany. With the demand for pDNA growing rap...

2019-12-11 09:06 2111

Kazia Initiates Preparatory Activities to Bring GDC-0084 into GBM AGILE, an International Phase II / III Study in Glioblastoma

SYDNEY, Dec. 11, 2019 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it's lead program, GDC-0084, has been selected to join GBM AGILE, an international, academic-led, multi-drug adaptive phase ...

2019-12-11 08:41 6442

Results of Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-developed by Innovent and IASO BIO Presented at the 2019 ASH Annual Meeting

SUZHOU, China, Dec. 10, 2019 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, today announced that th...

2019-12-10 16:00 4069
1 ... 297298299300301302303 ... 308